Omega-3 Fatty Acid Treatment in Multiple Sclerosis

Exclusion Criteria

• •A patient has to be excluded if he/she;
• •Has received continuous for more than one-week treatment with unsaturated fatty acids (omega-3) within 3 months prior to inclusion in the study.
• •Has an active RRMS disease that would strongly be recommended for standard immunomodulatory treatment by the treating neurologist.
• •Has received treatment with interferon-beta or glatiramer acetate within 6 months prior to inclusion in the study.
• •Has received treatment with lymphoid irradiation, mitoxantrone, cyclophosphamide or long-term glucocorticoids.
• •Has received treatment with azathioprine, cyclosporine or other immunosuppressive agents within the year prior to inclusion in the study.
• •Has received treatment with glucocorticoids or ACTH within two month prior to inclusion in the study.
• •Has experienced a relapse within one month prior to the inclusion in the study.
• •Has converted to secondary progressive MS.
• •Has suffered from major depression or any other psychiatric disorder that would preclude safe participation in the protocol.
• •Has diabetes mellitus.
• •Has alcohol or drug abuse.
• •Has cardiac insufficiency, cardiomyopathy, significant cardiac dysrhythmia, unstable or advanced ischemic heart disease (NYHA III or IV), or malignant hypertension.
• •Has renal insufficiency.
• •Has ASAT or ALAT \> 2,5 x normal upper limit.
• •Has leukopenia \< 2500 leukocytes per µl or thrombocytopenia \<100 000 thrombocytes per µl.
• •Has any systemic disease, which can influence his/her safety and compliance, or the evaluation of the disability.
• •Has thromboembolic disease that needs anticoagulative treatment.
• •Have formerly shown severe reactions against study drug, interferon-beta or gadolinium (MRI contrast).
• •Is breastfeeding or is pregnant.